Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P84103
UPID:
SRSF3_HUMAN
Alternative names:
Pre-mRNA-splicing factor SRP20; Splicing factor, arginine/serine-rich 3
Alternative UPACC:
P84103; B4E241; O08831; P23152; Q5R3K0
Background:
Serine/arginine-rich splicing factor 3 (SRSF3), also known as Pre-mRNA-splicing factor SRP20, plays a pivotal role in splicing factor, specifically promoting exon-inclusion during alternative splicing. It interacts with YTHDC1 to facilitate the recruitment of SRSF3 to mRNA-binding elements adjacent to m6A sites, enhancing exon-inclusion. Additionally, SRSF3 is involved in mRNA nuclear export by binding mRNA and enhancing NXF1-NXT1 RNA-binding activity, crucial for the TAP/NXF1 pathway.
Therapeutic significance:
Understanding the role of Serine/arginine-rich splicing factor 3 could open doors to potential therapeutic strategies.